In a retrospective study of GOG-0218, high plasma IL6 levels were found to be a clinical biomarker for predicting the efficacy of bevacizumab [123], suggesting that differences in plasma IL6 levels may reflect differences in tumor biology in OCCC. This evidence concerns the gene IL6 and neoplasm.